Cybin (HELP) EBIT (2020 - 2022)
Cybin (HELP) posted EBIT of $4.6 million for Q2 2022, up 3025.44% on a QoQ basis from $145656.7 in Q1 2021.
Cybin (HELP) EBIT (2020 - 2022) Analysis & Trends
Cybin's EBIT history runs 3 years deep, the most recent figure standing at $4.6 million for Q2 2022.
- Quarterly EBIT changed N/A year-over-year to $4.6 million in Q2 2022, while the trailing twelve-month figure through May 2022 was -$157.4 million (changed N/A YoY) and the FY2026 annual result came in at -$79.6 million, down 94.72% from the prior year.
- EBIT was $4.6 million for Q2 2022 at Cybin, up from $145656.7 in the prior quarter.
- Across five years, EBIT topped out at $144.2 million in Q2 2020 and bottomed at -$162.1 million in Q4 2020.
- A 3-year average of -$2.6 million and a median of $145656.7 in 2021 frame the typical range for EBIT.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Cybin | 262.76 Mn | 262.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2021 | 145,656.67 |
| Dec 31, 2020 | -162.14 Mn |
| Sep 30, 2020 | -1,921.84 |
| Jun 30, 2020 | 144.24 Mn |